# Clinical Trials Data KRAS - Document 45

# The Roles of Neutrophil Elastase in Lung Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01360931

"eligibilityCriteria": "Inclusion Criteria:\n\n\* All subjects undergoing clinical diagnostic or therapeutic procedures, including:\n\n 1. Fibreoptic bronchoscopy or pleuroscopy\n 2. Diagnostic or Therapeutic pleurocentesis AND who are mentally fit to give informed consent for donation of clinical specimens\n\nExclusion Criteria:\n\n\* Patients who cannot give written informed consent or refuse to give such consent for participation in this study",  
 "healthyVolunteers": true,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Subjects undergoing diagnostic bronchoscopy",

Question:  
Based on the following clinical trial information, would a patient with a KRAS gene mutation be eligible for the clinical trial?

Answer:  
Based on the clinical trial information provided, there is no specific mention of a KRAS gene mutation as part of the eligibility criteria. The inclusion and exclusion criteria primarily focus on the ability to undergo certain clinical procedures and the capacity to give informed consent. Therefore, a patient with a KRAS gene mutation would not be automatically excluded from the trial based on the criteria provided. However, it is always important to consult the full protocol or contact the trial coordinator for any additional details that might impact eligibility related to specific genetic factors.